Senseonics to acquire global commercial rights for Eversense CGM system.

PHC Holdings and Ascensia Diabetes Care have signed a preliminary agreement to transfer commercial operations for the Eversense Continuous Glucose Monitoring system to Senseonics Holdings. This move aims to streamline operations and may enhance the system's reach and accessibility.

Tokyo, Japan – September 4, 2025 – PHC Holdings Corporation (TSE: 6523) and its subsidiary Ascensia Diabetes Care have signed a memorandum of understanding (MOU) to transfer the commercial operations for the Eversense Continuous Glucose Monitoring (CGM) system to Senseonics Holdings, Inc. (NYSE American: SENS). The agreement aims to streamline operations and enhance the system's reach and accessibility.

Under the MOU, Senseonics will take over the commercial operations of Eversense, including research and development, manufacturing, and distribution. The transition is expected to begin on January 1, 2026, subject to a definitive agreement. Ascensia has held exclusive global distribution rights for Eversense since 2020 and launched the Eversense 365, the world’s first and only one-year CGM system, in the U.S. in October 2024.

The decision to transfer commercial operations to Senseonics aligns with PHC Group's long-term business strategy, known as the Value Creation Plan, which focuses on updating the company structure and portfolio to pursue operational efficiency. This move is also seen as an opportunity to accelerate the growth of Eversense, which has increasingly departed from Ascensia’s core blood glucose monitoring business.

Following the signing of the definitive agreement, most of the Eversense commercial team at Ascensia, including Brian Hansen, President of CGM, will transition to Senseonics. PHC Group and Ascensia plan to utilize Transition Service Agreements as needed while Senseonics establishes its global infrastructure. The companies anticipate minimal disruption for business partners, patients, and providers.

Koichiro Sato, Chief Operating Officer and Chief Strategy Officer of PHC Group and CEO of Ascensia, commented, "We are very proud to have worked with Senseonics on commercializing Eversense and we are committed to supporting Senseonics in establishing their own commercial operations and smoothly transitioning to them when we have a definitive agreement. PHC Group remains invested in Senseonics and will continue to explore additional growth opportunities in the diabetes space."

Tim Goodnow, President and Chief Executive Officer of Senseonics, commented, "Eversense is truly differentiated from any other CGM system on the market, and we believe now is the time to bring manufacturing and commercialization together to allow Senseonics to grow and remain responsive to the future needs of people with diabetes. We truly appreciate the partnership and investment that PHC Group and Ascensia have made in Senseonics, and we look forward to welcoming the talented commercial team and continuing to build momentum for Eversense 365."

References:

[1] https://www.phchd.com/global/news/2025/0904
[2] https://www.ainvest.com/news/senseonics-ascensia-diabetes-care-sign-mou-eversense-365-cgm-transition-2509/
[3] https://www.morningstar.com/news/business-wire/20250903537999/ascensia-diabetes-care-signs-mou-to-transfer-eversense-cgm-distribution-to-strategic-partner-senseonics